A Phase 3 interventional study of Rotigotine in Advanced Parkinson's Disease, sponsored by UCB BIOSCIENCES GmbH. Completed at 22 sites in 5 countries. Open to participants aged 30 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-06-03.
Sponsored by UCB BIOSCIENCES GmbH (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.
Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 23rd largest by enrollment of the 42 interventional ones that give a count, is one of 8 that started in 2012, is one of 20 in phase 3, and was the 32nd registered.
4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.
Browse Parkinson Disease studies →1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:
Eva Pharma
Ages 30+
rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →
Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.
This study: 30 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 9 · Phase 3 22 · Phase 4 8
First in 1999; this study’s year is marked. 8 started in 2012.
This study's enrollment of 90 is above the median of 40 across 3,355 interventional studies indexed under Parkinson Disease.
Median enrollment 123 across the 42 interventional studies. Of the 41 that completed or were terminated, 30 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under UCB BIOSCIENCES GmbH, one of the names counted as UCB S.A.. Under that name alone:
UCB BIOSCIENCES GmbH is the lead sponsor of 21 studies on the registry; none are open to participants now.
44 studies in Parkinson Disease by UCB S.A.: none open now, none under way, none of them phase 3. Of 44 finished, 29 (66%) have results posted.
Among the 44 studies in Parkinson Disease by UCB S.A., this one is the 20th largest by enrollment of the 34 interventional ones that give a count, is one of 8 that started in 2012, is one of 19 in phase 3, and was the 32nd registered.
UCB S.A.’s Parkinson Disease studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing rotigotine in Parkinson Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 44 in Parkinson Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is to investigate the safety and efficacy of Rotigotine add-on therapy with low doses of Pramipexole or Ropinirole in patients with advanced-stage Parkinson's Disease (PD) who have insufficient response to L-dopa and low doses dopamine receptor agonists.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
- Titration Period: Weekly titration to the subject's optimal dose of Rotigotine between 2 mg/24 h and 8 mg/24 h. In case of intolerable Adverse Events (AEs) one back-titration is allowed during the Titration Period. Duration of the Titration Period: Between 1 week and 5 weeks. - Maintenance Period: Starts once subject reached either optimal or maximal dose of Rotigotine. Subjects receive stable dose of Rotigotine throughout the Maintenance Period. No back-titration is allowed during the Maintenance Period. Duration of the Maintenance Period: Between 3 weeks and 7 weeks.
Drug: Rotigotine
Application of Rotigotine up to 8 mg/24 h patches for 24 hours.
Also known as: Neupro
Clinical Global Impression (CGI) Item 4 (Side Effects) at the End of the Treatment Period
The CGI Item 4 was used to assess side effects. It ranges from 0 to 4 as follows: 0 = Side effects not assessable 1. = No side effects 2. = Side effects do not significantly interfere with subject's functioning 3. = Side effects significantly interfere with the subject's functioning 4. = Side effects outweigh therapeutic efficacy.
Time frame: Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)
Change From Baseline to the End of the Treatment Period in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III ("on" State) Total Score
The Unified Parkinson´s Disease Rating Scale Part III is an accepted and validated scale for the assessment of motor function in Parkinson´s disease. Each of the 27 sub-items in the UPDRS III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities. The total scores therefore ranges from 0 to 108. A negative value in Change from Baseline to Week 8 indicates an improvement in motor functions from Baseline.
Time frame: From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)
Change From Baseline to the End of the Treatment Period in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Average of "on" and "Off" State) Total Score
UPDRS Part II measures 'Activities in Daily Living'. The total score ranges from 0 (Best score possible) to 52 (Worst score possible). UPDRS Part II total score (average of "on" and "off" state) is the average of UPDRS Part II total score ("on" state) and Part II total score ("off" state). A negative value in Change from Baseline to Week 8 indicates an improvement in activities in daily living from Baseline.
Time frame: From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)
Change From Baseline to the End of the Treatment Period in Absolute Time Spent "Off"
Absolute time spent "off" is measured in hours per day. A negative value in Change from Baseline to Week 8 indicates that the time spent "off" decreased from Baseline and therefore indicates an improvement from Baseline. Only subjects with time spent "off" at Baseline (subset of the Full Analysis Set (FAS)) are included in the analysis of this outcome measure.
Time frame: From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)
Change From Baseline to the End of the Treatment Period in Time Spent "on" Without Troublesome Dyskinesia
Absolute time spent "on" without troublesome dyskinesia is measured in hours per day. A positive value in Change from Baseline to Week 8 indicates that the time spent "on" without troublesome dyskinesia increased from Baseline and therefore indicates an improvement from Baseline.
Time frame: From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)
Change From Baseline to the End of Treatment Period in Parkinson's Disease Sleep Scale 2 (PDSS-2) Total Score
The Parkinson´s Disease Sleep Scale (PDSS) is a questionnaire with 15 questions to assess sleep disturbance and nocturnal disability in Parkinson´s disease. The item- scores can range between 0= never and 4= very often. The PDSS score is a sum score of all 15 questions. A negative value in Change from Baseline to Week 8 indicates an improvement from Baseline.
Time frame: From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)
Change From Baseline to the End of Treatment Period in the Pittsburgh Sleep Quality Index (PSQI) Global Score
The Pittsburgh Sleep Quality Index (PSQI) is a questionnaire with 18 questions to assess sleep quality. The 18 questions are distributed to 7 elements with each element ranging from 0-3. The global score is the sum score of all 7 elements and ranges from 0-21 with higher values indicating worse sleep quality. A negative value in Change from Baseline to Week 8 indicates an improvement in sleep quality from Baseline.
Time frame: From Baseline (Week 0) to Week 8 (Visit 8) of the 8 weeks Treatment Period (Titration and Maintenance Period)
This multicenter study started to enroll subjects in 5 countries in October 2012.
| Milestone | Rotigotine |
|---|---|
| Started | 90 |
| Completed | 79 |
| Not completed | 11 |
| Withdrew: Noncompliant | 3 |
| Withdrew: Adverse event | 5 |
| Withdrew: Unable to follow protocol/ judged by inv | 3 |
The CGI Item 4 was used to assess side effects. It ranges from 0 to 4 as follows: 0 = Side effects not assessable 1. = No side effects 2. = Side effects do not significantly interfere with subject's functioning 3. = Side effects significantly interfere with the subject's functioning 4. = Side effects outweigh therapeutic efficacy.
| participants | Rotigotine |
|---|---|
| CGI Item 4 score of 1 | 61 |
| CGI Item 4 score of 2 | 22 |
| CGI Item 4 score of 3 | 3 |
| CGI Item 4 score of 4 | 3 |
| CGI Item 4 score of 3 or 4 | 6 |
The Unified Parkinson´s Disease Rating Scale Part III is an accepted and validated scale for the assessment of motor function in Parkinson´s disease. Each of the 27 sub-items in the UPDRS III is measured on a scale of 0 to 4, where 0 is normal and 4 represents severe abnormalities. The total scores therefore ranges from 0 to 108. A negative value in Change from Baseline to Week 8 indicates an improvement in motor functions from Baseline.
| units on a scale | Rotigotine |
|---|---|
| Change From Baseline to the End of the Treatment Period in the Unified Parkinson's Disease Rating Scale (UPDRS) Part III ("on" State) Total Score | -5.3 ± 8.3 |
UPDRS Part II measures 'Activities in Daily Living'. The total score ranges from 0 (Best score possible) to 52 (Worst score possible). UPDRS Part II total score (average of "on" and "off" state) is the average of UPDRS Part II total score ("on" state) and Part II total score ("off" state). A negative value in Change from Baseline to Week 8 indicates an improvement in activities in daily living from Baseline.
| units on a scale | Rotigotine |
|---|---|
| Change From Baseline to the End of the Treatment Period in the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Average of "on" and "Off" State) Total Score | -1.5 ± 3.8 |
Absolute time spent "off" is measured in hours per day. A negative value in Change from Baseline to Week 8 indicates that the time spent "off" decreased from Baseline and therefore indicates an improvement from Baseline. Only subjects with time spent "off" at Baseline (subset of the Full Analysis Set (FAS)) are included in the analysis of this outcome measure.
| hours/day | Rotigotine |
|---|---|
| Change From Baseline to the End of the Treatment Period in Absolute Time Spent "Off" | -2.1 ± 2.9 |
Absolute time spent "on" without troublesome dyskinesia is measured in hours per day. A positive value in Change from Baseline to Week 8 indicates that the time spent "on" without troublesome dyskinesia increased from Baseline and therefore indicates an improvement from Baseline.
| hours/day | Rotigotine |
|---|---|
| Change From Baseline to the End of the Treatment Period in Time Spent "on" Without Troublesome Dyskinesia | 1.9 ± 3.1 |
The Parkinson´s Disease Sleep Scale (PDSS) is a questionnaire with 15 questions to assess sleep disturbance and nocturnal disability in Parkinson´s disease. The item- scores can range between 0= never and 4= very often. The PDSS score is a sum score of all 15 questions. A negative value in Change from Baseline to Week 8 indicates an improvement from Baseline.
| units on a scale | Rotigotine |
|---|---|
| Change From Baseline to the End of Treatment Period in Parkinson's Disease Sleep Scale 2 (PDSS-2) Total Score | -3.2 ± 7.5 |
The Pittsburgh Sleep Quality Index (PSQI) is a questionnaire with 18 questions to assess sleep quality. The 18 questions are distributed to 7 elements with each element ranging from 0-3. The global score is the sum score of all 7 elements and ranges from 0-21 with higher values indicating worse sleep quality. A negative value in Change from Baseline to Week 8 indicates an improvement in sleep quality from Baseline.
| units on a scale | Rotigotine |
|---|---|
| Change From Baseline to the End of Treatment Period in the Pittsburgh Sleep Quality Index (PSQI) Global Score | -0.7 ± 3.0 |
Collected over Adverse Events (AEs) were collected over the whole study duration from the Screening Period (Day -28 to Day -7) to the Safety Follow-up Visit (up to Day 78).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rotigotine | — | 5/90 (5.6%) | 35/90 (38.9%) |
| Event | Rotigotine |
|---|---|
| Subdural haemorrhageInjury, poisoning and procedural complications | 1/90 |
| Nasopharyngeal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/90 |
| Confusional statePsychiatric disorders | 1/90 |
| DeliriumPsychiatric disorders | 1/90 |
| HallucinationPsychiatric disorders | 1/90 |
| Urinary retentionRenal and urinary disorders | 1/90 |
| Event | Rotigotine |
|---|---|
| Application site pruritusGeneral disorders | 12/90 |
| DizzinessNervous system disorders | 9/90 |
| Orthostatic hypotensionVascular disorders | 9/90 |
| NauseaGastrointestinal disorders | 7/90 |
| DyskinesiaNervous system disorders | 7/90 |
| NasopharyngitisInfections and infestations | 5/90 |
Baseline characteristics refer to the Safety Set. The Safety Set consists of all subjects who had at least one patch application.
| Age, Continuous(years) | Rotigotine |
|---|---|
| Mean | 61.3 ± 9.3 |
| Age, Customized(participants) | Rotigotine |
|---|---|
| < 65 years | 57 |
| >= 65 years | 33 |
| Sex: Female, Male(Participants) | Rotigotine |
|---|---|
| Female | 43 |
| Male | 47 |
| Region of Enrollment(participants) | Rotigotine |
|---|---|
| Taiwan | 8 |
| Malaysia | 6 |
| Singapore | 4 |
| Australia | 6 |
| Korea, Republic of | 66 |
The record gives a start of Oct 2012, a primary completion of Mar 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rotigotine